Triazines

Investigational Magrolimab in Combination With Azacitidine Demonstrates Durable Activity in Previously-Untreated Myelodysplastic Syndrome and Acute Myeloid Leukemia

Retrieved on: 
Friday, May 29, 2020
Oncology, Health, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Lactams, Nucleosides, Triazines, Azacitidine, 7+3, Chemical substances, Chemistry, Branches of biology

Results continue to support the clinical activity of magrolimab and azacitidine.

Key Points: 
  • Results continue to support the clinical activity of magrolimab and azacitidine.
  • Responses to magrolimab and azacitidine also deepened over time, as the CR rate with at least six months of follow-up was 56 percent in MDS patients.
  • Notably in TP53-mutant AML (n=12), a treatment refractory and poor prognosis population, 75 percent achieved a CR or CRi.
  • The safety profile of the combination of magrolimab plus azacitidine was generally consistent with prior reports with no maximum tolerated dose reached.

AbbVie Data at EHA Annual Congress Highlight Depth and Breadth of Transformative Blood Cancer Portfolio

Retrieved on: 
Friday, May 15, 2020
Chemical compounds, Organic compounds, Heterocyclic compounds, Orphan drugs, Breakthrough therapy, Triazines, Piperazines, Oncogenes, Venetoclax, Bcl-2, Ivosidenib, IDH1

; Abstract #S157

Key Points: 
  • ; Abstract #S157
    Kinetics of Response in the Peripheral Blood Predicts Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Bloodwise TAP CLARITY trial.
  • ; Abstract #EP535
    Real-World Data (RWD) Cohort of Patients with Acute Myeloid Leukemia (AML) in the United States from an Electronic Health Record (EHR)Derived De-Identified Database.
  • ; Abstract #EP1739
    Phase 1b/2 Study of the IDH1-Mutant Inhibitor Ivosidenib with the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies.
  • In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis.

Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine in Patients with High/Very-high Risk Myelodysplastic Syndromes

Retrieved on: 
Wednesday, May 13, 2020
Health, Lactams, Nucleosides, Triazines, Orphan drugs, Azacitidine, Myelodysplastic syndrome, Clinical endpoint, Chemical substances, Medicine, Vadastuximab talirine

The study results will be featured in a poster at the American Society of Clinical Oncology 2020 Virtual Scientific Program.

Key Points: 
  • The study results will be featured in a poster at the American Society of Clinical Oncology 2020 Virtual Scientific Program.
  • "These data are promising and I continue to be encouraged by my experience to date with the combination of pracinostat and azacitidine evaluated in this study.
  • The primary endpoints were safety and tolerability of pracinostat in combination with azacitidine and ORR, defined as CR plus partial response (PR).
  • It is also being evaluated in a Phase 2 study in patients with high or very high-risk myelodysplastic syndrome ("MDS").

Onconova Therapeutics Strengthens Board of Directors with Nomination of Life Sciences Industry Veteran

Retrieved on: 
Monday, April 27, 2020
Azacitidine, Lactams, Nucleosides, Triazines, Management, Chemical substances, Chemistry, Articles

Having been a key executive in the launch of azacitidine in MDS, Terri Shoemaker will be a valuable addition to our Board of Directors, said Chairman Michael Hoffman.

Key Points: 
  • Having been a key executive in the launch of azacitidine in MDS, Terri Shoemaker will be a valuable addition to our Board of Directors, said Chairman Michael Hoffman.
  • We believe that Ms. Shoemaker's experience and specific skills in developing and managing commercial organizations in the life science industry will be instrumental in our efforts moving forward.
  • She has extensive experience in senior leadership roles with a broad range of commercial and operational expertise in the life science industry.
  • It is an honor to be joining Onconovas talented Board of Directors at a pivotal time for the company, said Ms.Shoemaker.

Genentech Announces Venclexta Combination Improved Overall Survival in People With Previously Untreated Acute Myeloid Leukemia

Retrieved on: 
Monday, March 23, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Chemical compounds, Organic compounds, RTT, Cancer, Acute myeloid leukemia, Lactams, Nucleosides, Triazines, Hypomethylating agent, Leukemia, Chronic lymphocytic leukemia, Venetoclax, the VIALE-A Study, AML, Venclexta, Genentech in Hematology, Genentech

Venclexta (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone.

Key Points: 
  • Venclexta (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone.
  • Two-thirds of patients received 400 mg Venclexta daily, in combination with azacitidine, and the remaining patients received placebo tablets in combination with azacitidine.
  • Acute myeloid leukemia (AML) is the most common type of aggressive leukemia in adults, which has the lowest survival rate for all types of leukemia.
  • In the United States, Venclexta has been granted five Breakthrough Therapy Designations by the U.S. Food and Drug Administration: one for previously untreated chronic lymphocytic leukemia (CLL), two for relapsed or refractory CLL and two for previously untreated acute myeloid leukemia.

Russia Melamine-Formaldehyde Resin Market, 2020 - Consumption, Production, Import, Export, Prices & Sales - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 12, 2020
Chemicals, Plastics, Manufacturing, Chemical compounds, Chemistry, Goods economics), Melamine, Polyamines, Triazines, Formaldehyde, Protein adulteration in China, Melamine resin

Our business analysis of the melamine-formaldehyde resin market gives key information about the state of this market for 2019, as well as a forecast on the development of melamine-formaldehyde resin from 2019 till 2023.

Key Points: 
  • Our business analysis of the melamine-formaldehyde resin market gives key information about the state of this market for 2019, as well as a forecast on the development of melamine-formaldehyde resin from 2019 till 2023.
  • Our rating of the largest melamine-formaldehyde resin producers in the Russian market is based on the assessment of the financial parameters of melamine-formaldehyde resin producers.
  • The publisher annually creates a rating of melamine-formaldehyde resin producers on the basis of data from melamine-formaldehyde resin manufacturers in Russia.
  • Melamine-formaldehyde resin import by countries, import structure
    Melamine-formaldehyde resin import by regions, import structure
    Melamine-formaldehyde resin import by countries, import structure
    Melamine-formaldehyde resin import by regions, import structure
    Melamine-formaldehyde resin export by countries, export structure
    Melamine-formaldehyde resin export by regions, export structure
    Melamine-formaldehyde resin export by countries, export structure
    Melamine-formaldehyde resin export by regions, export structure
    2.

Research Department Explosive Market Size | US$ 13 Bn by 2026

Retrieved on: 
Monday, March 9, 2020
Nitroamines, RDX, Triazines, Explosive, Explosives, Chemistry

LOS ANGELES, March 9, 2020 /PRNewswire/ -- The Size of Research Department Explosive (RDX) Market is expected to reach around US$ 13 billion by 2026.

Key Points: 
  • LOS ANGELES, March 9, 2020 /PRNewswire/ -- The Size of Research Department Explosive (RDX) Market is expected to reach around US$ 13 billion by 2026.
  • The global research department explosive (RDX) market is anticipated to grow at significant CAGR around 2.8% throughout the forecast period 2019 to 2026.
  • Due to the high demand in defence, mining, and construction industries, North America Research Department Explosive markets is likely to show considerable growth.
  • The global research department explosive (RDX) market is characterized by the presence of experienced and established players.

Astex Pharmaceuticals Announces U.S. Food and Drug Administration (FDA) Acceptance for Review of an NDA for the Combination Oral Hypomethylating Agent Cedazuridine and Decitabine (ASTX727 or oral C-DEC), for the Treatment of MDS and CMML

Retrieved on: 
Tuesday, February 11, 2020
FDA, Health, Pharmaceutical, Clinical trials, Oncology, RTT, Nucleosides, Chemical compounds, Organic compounds, Lactams, Blood disorders, Triazines, Myelodysplastic syndrome, Decitabine, Acute myeloid leukemia, 7+3, Leukemia, C-DEC (Cedazuridine 100 mg and Decitabine 35 mg) Fixed-Dose Combination, the Phase 3 ASCERTAIN Study, Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML), Astex Pharmaceuticals, Inc.

The NDA submission is based on data from the ASCERTAIN phase 3 study which evaluated the 5-day decitabine exposure equivalence of oral C-DEC and IV decitabine.

Key Points: 
  • The NDA submission is based on data from the ASCERTAIN phase 3 study which evaluated the 5-day decitabine exposure equivalence of oral C-DEC and IV decitabine.
  • The phase 3 study is now being extended to include patients with acute myeloid leukemia (AML) unsuitable to receive intensive induction chemotherapy.
  • In September 2019 Astex announced that C-DEC had received orphan drug designation for the treatment of MDS and CMML from the U.S. FDA.
  • An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.

Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation

Retrieved on: 
Thursday, January 30, 2020
Branches of biology, Health, Lactams, Nucleosides, Triazines, Azacitidine, P53, Clinical trial

Breakthrough Therapy Designation further supports our development program for APR-246 in combination with azacitidine in MDS patients with a TP53 mutation, said Christian S. Schade, Chief Executive Officer of Aprea.

Key Points: 
  • Breakthrough Therapy Designation further supports our development program for APR-246 in combination with azacitidine in MDS patients with a TP53 mutation, said Christian S. Schade, Chief Executive Officer of Aprea.
  • Outcomes for MDS patients with a TP53 mutation are poor and there are no current therapeutic options specifically for these patients.
  • We look forward to continued interaction with FDA regarding our ongoing Phase 3 clinical study and our clinical development program to advance APR-246.
  • A pivotal Phase 3 clinical trial of APR-246 and azacitidine for frontline treatment of TP53 mutant MDS is ongoing.

Decontaminating pesticide-polluted water using engineered nanomaterial and sunlight

Retrieved on: 
Wednesday, January 15, 2020
Chemistry, Physical sciences, Chemical compounds, Herbicides, Triazines, Atrazine, Chloroarenes, Xenoestrogens, Ultraviolet, Drinking water, Sunlight, Water

Atrazine is found throughout the environment, even in the drinking water of millions of people across the country.

Key Points: 
  • Atrazine is found throughout the environment, even in the drinking water of millions of people across the country.
  • "By working synergistically, we were able to develop a water treatment process that we would never have been able to achieve separately.
  • visible light in addition to UV, Professor El Khakani had to make the TiO2 films sensitive to visible sunlight.
  • When using actual water samples, only 8 percent of the atrazine was degraded initially.